NEW HOLDER OF IVX - Whats the Scoop?, page-4

I thought I might take the trouble to reply to your request. Firstly let me say that in buying any share at a price less than one cent, you have to accept that you may lose your money. It is the death zone. However, in my opinion, IVX is the most compelling risk/reward proposition I have ever seen on the stock market. I have followed this stock for a good number of years and have done a lot of research. There are people who paid $3.00 for the shares you bought for $0.003 and have never sold a share. I am not speaking about myself.
I did an analysis about a year ago and came to the conclusion that the net present value, on conservative assumptions, of one drug, Nadolol, for the USA market alone, was over $1B. IVX have two other drugs, Zafirlukast and CPn10. Forget CPn10 as it requires substantial expenditure and is the least valuable property, but not by any means without value.
Both the other two are generic drugs which are proven safe and have been used in millions of patients. Nadolol is a drug licensed for use in heart patients. It has been trialled and is proposed for use in pulmonary indications, principally in an inhaled form. The major hurdle, delivering it as an inhaled product, in measured doses has been solved. It is safe and has been shown as the only agent in prospect which actually heals damage to the lung, rather than just ameliorating the condition, which is all that can be claimed for the current treatments. This is a $30B market.
Zafirlukast is proposed for treatment of acute asthma. It is the only non-steroidal treatment available for asthma. It is used as an oral drug and has some pretty nasty side effects, so is used sparingly. The proposal is to deliver it in an inhaled form.
This is delivered directly to the lung, requiring about 2% of the dose required orally, practically eliminating side effects. One of the majors tried to market this as an inhaled product over twenty years ago. They had almost completed trials with CFC as the propellant. At this time CFCs were banned over the "hole in the ozone layer" and the work was abandoned. IVX acquired the rights and, along with their partners, have solved the issue of a propellant to provide measured doses in an inhaler.
The management are experienced and honest, at least by reputation. The directors have personally lent the company $1M to bail it out of a disaster. They cannot raise any more money at the current price and the only solution is to sell the assets to someone and get an over-riding royalty. They will do a deal of some such, in my opinion, before they run out of money. The royalty is likely to be at least 5% of sales and the potential market is in excess of $10B.
All this is in my opinion. You may think this is cloud cuckoo land stuff, but I firmly believe in this company and the people behind it. It is not for the faint hearted, but at current prices you don't have a lot to lose.
The company has simply run out of money, helped by a couple of very poor financing deals.